The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
The present disclosure relates to agonists of Tacr2, such as peptides agonist of Tacr2 and methods of using the same for treatment of insulin resistance, obesity and/or diabetes. The disclosure also relates to use of said agonists of Tacr2 for enhancement of energy consumption in an individual.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 3/04 - Anorexigènes; Médicaments de l'obésité
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 5/50 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques pour augmenter ou potentialiser l'activité de l'insuline
The present invention relates to modular nanoparticle-based compositions based on nucleic acids, such as DNA and RNA, which are particularly useful in prophylaxis and/or treatment of diseases and disorders.
The present invention relates to mutated bacterial host cells, said host cells producing a polypeptide of interest and having at least one disrupted flagellum gene, and to nucleic acid constructs and vectors encoding at least one flagellum polypeptide with reduced or eliminated activity as well as to methods of producing one or more polypeptide of interest in said host cells.
C07K 14/32 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Bacillus (G)
C12N 15/75 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p.ex. Lactobacillus, Micromonospora pour Bacillus
C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p.ex. hyaluronidase, invertase, amylase
C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
The present invention relates to a drug delivery platform. In particular, it relates to a foil-based drug delivery platform for delivery to the intestine.
The present invention relates to co-amorphous form of a substance and a protein. The present invention also relates to pharmaceutical, cosmetic or veterinary compositions comprising the co-amorphous form as well as to methods for preparing and using the co-amorphous form.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
7.
LYSOSOMAL ENZYMES MODIFIED BY CELL BASED GLYCOENGINEERING
The present invention relates to lysosomal enzymes modified by use of cell based methods, a compositions comprising a modified lysosomal enzyme, as well as methods for producing a modified lysosomal enzyme and therapeutic use of such modified lysosomal enzyme. In particular, the present disclosure relates to a modified lysosomal enzyme which has low Man6P and low exposed Mannose and high sialic acid content of alpha2,3 type enabling long circulation time and improved uptake into difficult-to-reach organs like heart, kidney and brain.
C12N 9/40 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-galactose-glycoside, p.ex. alpha-galactosidase
C12P 21/00 - Préparation de peptides ou de protéines
The present disclosure relates to methods for assessing the effects of a mutation of interest in a cell. Herein are also disclosed systems for assessing the effects of a mutation of interest in a cell. The disclosure also provides host cells and host cell populations comprising the system.
The present invention relates to virally expressed peptides which bind to PDZ domains and thereby block PDZ domain mediated protein-protein interactions and expression vectors encoding these peptides. The virally expressed peptides comprise an oligomerization domain, capable of forming higher order constructs, such as trimers or tetramers, and a peptide ligand capable of binding to a PDZ domain. The invention furthermore relates to therapeutic use of said peptides and expression vectors encoding these peptides.
The present disclosure relates to a lipid conjugated bivalent peptide ligand which bind to Protein Interacting with C Kinase-1 (PICK1) and thereby inhibit PICK1. The PICK1 inhibitors of the present disclosure comprise a peptide portion comprising two peptide ligands of PICK1, and a non-peptide portion comprising a linker, linking the two peptide ligands, and a lipid. The disclosure furthermore relates to therapeutic and diagnostic use of said PICK1 inhibitor for treatment of diseases or disorders associated with maladaptive plasticity.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
11.
BIODEGRADABLE COMPOSITE MATERIAL OF PURE AMYLOSE AND CELLULOSE NANOFIBRES OR CELLULOSE NANOCRYSTALS
Disclosed herein are composite materials comprising amylose, cellulose nanofibres or cellulose nanocrystals, and a plasticiser. The amylose is of high purity, specifically containing little or no amylopectin. The cellulose nanofibres or cellulose nanocrystals act to reinforce the disclosed composite materials. Also disclosed are methods of producing such composite materials, and their use.
A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and/or (2) at least 5% of all of the glial cells in the white matter of the brain and/or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.
The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A betalain pigment composition from red beet plants including pre-harvest foliar spraying of an ethylene-generating compound and the use of the obtained betalain pigment composition for coloring of an edible product
A23L 5/43 - Adjonction de colorants ou de pigments, p.ex. en combinaison avec des azurants optiques en utilisant des colorants ou des pigments organiques d'origine naturelle, leurs doublons artificiels ou leurs dérivés
A23K 20/179 - Agents colorants, p.ex. agents de pigmentation ou de teinture
A01G 22/25 - Légumes-racines, p.ex. pommes de terre, ignames, betterave ou wasabi
The present disclosure is directed to systems for in vivo tracking of target cells resulting from implantation of a preparation of cells. The present disclosure is further directed to in vivo methods of tracking a preparation of cells implanted in a subject, and of preparations of cells.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
17.
ISOLATION OF BONA FIDE PANCREATIC PROGENITOR CELLS
The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
A61P 3/08 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose
G01N 33/566 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
18.
CYCLIC PEPTIDE INHIBITORS OF PSD-95 AND USES THEREOF
The present invention relates novel cyclic peptides which can act as inhibitors of protein-protein interactions, specifically by inhibiting the PDZ2 domain of PSD-95, as well as their use in treatment of excitotoxic-related diseases and neuropathic pain.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present invention provides novel PSMA targeting urea-based ligands that binds to prostate-specific membrane antigen (PSMA) which is expressed 8-to-12-fold higher in prostate cancer cells when compared to healthy tissue. The PSMA targeting urea-based ligands comprises a chelating agent that may comprise a metal and a halogen radioisotope of fluorine, iodine, bromine or astatine. The invention further relates to a method for providing the PSMA targeting urea-based ligands of the invention, to precursors of the PSMA targeting urea-based ligands and to the PSMA targeting urea-based ligands use in radiotherapy, imaging and theranostic.
Nederlands Instituut voor Ecologie (Nioo-Knaw) (Pays‑Bas)
University of Copenhagen (Danemark)
Inventeur(s)
De Bruijn, Irene
Raaijmakers, Josephus Maria
Buchman, Kurt
Abrégé
The invention relates to the use of bacterial lipopeptide biosurfactants in the treatment of white spot disease in fresh water and marine fish. Particularly useful for treatment of white spot disease are viscosin-like lipopeptide biosurfactants obtainable from the Pseudomonas fluorescens strain H6, massetolide or a derivative thereof and putisolvin or a derivative thereof.
The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.
Board of Trustees of Michigan State University (USA)
University of Copenhagen (Danemark)
Inventeur(s)
Ntana, Fani
Collinge, David B.
Hamberger, Björn
Bhat, Wajid Waheed
Johnson, Sean
Jensen, Birgit
Jorgensen, Hans Jorgen Lyngs
Abrégé
Constructs, host cells, fungi, seeds, plants, and methods are described herein can include a Serendipita indica terpenoid synthase (SiTPS). Such constructs host cells, fungi, seeds, plants, and methods are useful, for example, for making viridiflorol. As described herein, the basidionycete Serendipita indica, a non-specific-host root endophyte fungus, possesses a functional terpenoid synthase gene (SiTPS). Heterologous expression of SiTPS in host cells showed that the produced protein efficiently utilizes the fifteen-carbon precursor farnesylpyrophosphate (FTP) to synthesize the sesquiterpene alcohol viridiflorol, shown below.
Provided is a quantum computing device comprising a carbon nanotube, a superconducting substrate in quantum proximity to the nanotube and being in a superconducting state having a pairing correlation matrix with a substantial spin-triplet component in a direction perpendicular to the nanotube, and a magnet arranged to provide a longitudinal magnetic field along a longitudinal axis of the nanotube. Further provided is a quantum computing device comprising at least three substrates made of a superconductor material and each in a superconducting state, and a non-superconducting structure made of a material in which the electrons' closed trajectories experience strong spin-orbit coupling interactions and being in quantum proximity to the substrates. The sum of the phase differences between the order parameters of all of the substrates is at least π.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
H01L 39/12 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails caractérisés par le matériau
H01L 39/22 - Dispositifs comportant une jonction de matériaux différents, p.ex. dispositifs à effet Josephson
24.
POSITIVE ALLOSTERIC MODULATORS OF THE CALCIUM-SENSING RECEPTOR
The present invention relates to non-naturally occurring antibodies or active antibody fragments specifically binding the calcium-sensing receptor (CaSR), acting as positive allosteric modulators (PAMs) to provide for potent therapeutic agents. More particular, the immunoglobulin single variable domains (ISVDs) identified herein reveal a novel therapeutic strategy to reduce parathyroid hormone release in a subject, and are therefore suitable for treatment of hypercalcemia disorders. Moreover, co-application of such an ISVD and a synthetic PAM or calcimimetic results in a synergistic agonistic CaSR activity providing for pharmaceutical compositions as next generation CaSR drugs.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 5/20 - Médicaments pour le traitement des troubles du système endocrinien des hormones parathyroïdiennes pour réduire, bloquer ou contrarier l'activité de la PTH
25.
A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE
The present invention describes a uPAR-targeting peptide conjugate comprising a fluoro bore, a peptide binding to uPAR and a linker group which are connected by covalent bonds, wherein the uPAR-targeting peptide conjugate may be used as fluorescence probe in real time optical imaging and delineation of cancer tumors or metastases during surgery.
The invention relates to a method for controlling of a biofilm, for removing a formed biofilm and/or for controlling a growth of microorganisms, preferably bacteria, in an aqueous environment of an industrial manufacturing process comprising cellulosic fibre material. In the method a composition comprising a compound selected from a group consisting of 3-[(4-methylphenyl)sulphonyl]-2-propenenitrile and 4-amino-N-2-thiazolyl-benzenesulphonamide is administered to the aqueous environment of the process.
A device for generating individual photons with energy E includes quantum emitters, having at least one determined transition with the energy E from an energy level N* to a lower energy level N1. The emitters are near a propagation path running from first to second regions. The device also includes at least one light source to output light, for propagation along the path. The light has the energy E for resonant excitation of the energy level N*. The emitters are arranged so that optionally exactly Z emitters are illuminated, forming an optical thickness τ>0 for the light along the path. The number Z lies in a range of Z0±10% and Z0 is a number at which a maximum destructive interference in the second region occurs between a two-photon component of the light scattered on the ZO emitters and a two-photon component of the non-scattered light.
A compound for use in the treatment of CNS disorders with sleep disturbances e.g. narcolepsy or Angelman syndrome in a subject, wherein said compound is according to formula (I) or any isomer, tautomer, enantiomer, racemic form or deuterated form thereof, or a pharmaceutically acceptable salt thereof.
The invention provides methods for identifying biomarkers in a patient's microbiota to predict a patient's response to a predetermined diet to promote weight loss and methods of promoting weight loss or treating obesity in the patient by optimizing the patient's diet in accordance with the biomarkers identified in the patient's gut microbiota. The methods of the invention can also be used to manage or maintain weight, i.e., prevent or inhibit weight gain, in a patient who is of normal weight or is overweight or obese.
C12Q 1/40 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase une amylase
A61P 3/04 - Anorexigènes; Médicaments de l'obésité
A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
31.
Method for manufacture of nanostructure electrical devices
The present disclosure further relates to nanostructures, in particular hybrid nanostructures with patterned growth of various layers for use in nanoscale electronic devices, such as hybrid semiconductor nanostructures with patterned growth and/or deposition of superconducting material for use in quantum devices. The presently disclosed method can be utilized for in-situ manufacturing of nanoscale electronic devices that have not been contaminated by ex-situ processes. One embodiment relates to a method for manufacturing a substrate for growth of crystalline nanostructures, the method comprising the steps of: depositing one or more layers of a crystal growth compatible dielectric material, such as silicon oxide, in a predefined pattern on the surface of a crystal growth compatible substrate to create a predefined etch pattern of said crystal growth compatible material, and selectively etching the substrate surface around said etch pattern to provide at least one under-etched platform which is vertically raised from the etched substrate surface.
H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
H01L 39/24 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement des dispositifs couverts par ou de leurs parties constitutives
32.
Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid
The present invention relates to lysosomal enzymes modified by use of cell based methods, a compositions comprising a modified lysosomal enzyme, as well as methods for producing a modified lysosomal enzyme and therapeutic use of such modified lysosomal enzyme. In particular, the present disclosure relates to a modified lysosomal enzyme which has low Man6P and low exposed Mannose and high sialic acid content of alpha2,3 type enabling long circulation time and improved uptake into difficult-to-reach organs like heart, kidney and brain.
C12N 9/40 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-galactose-glycoside, p.ex. alpha-galactosidase
C12P 21/00 - Préparation de peptides ou de protéines
The present invention relates to a vaccine comprising a nucleic acid construct such as a DNA construct especially a nucleic acid construct comprising sequences encoding invariant chain operatively linked to antigenic protein or peptide encoding sequences. The present vaccine stimulates an enhanced immune response.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
The invention regards a composite for environmental remediation, comprising: —one or more green rust compound(s) or green rust precursor(s), and—one or more biochar(s).
B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
B01J 20/02 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique
B01J 20/06 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des oxydes ou des hydroxydes des métaux non prévus dans le groupe
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
The present invention relates to virally expressed peptides with high affinity for the PDZ domains, such as the PDZ domain of PICK1. The invention furthermore relates to the therapeutic use of these peptides in prevention and/or treatment of diseases and/or disorders associated with maladaptive plasticity and/or transmission.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
A mechanical resonator device. The resonator device includes a resonator element made of an elastic material under tensile stress and adapted for sustaining at least one oscillation mode; and a clamping structure supporting the resonator element. The clamping structure has a phononic density of states exhibiting a bandgap or quasi-bandgap such that elastic waves of at least one polarisation and/or frequency are not allowed to propagate through the clamping structure. The resonator element and the clamping structure are configured to match with a soft-clamping condition that elastic waves of polarisation and/or frequency corresponding to the at least one oscillation mode of the resonator penetrate evanescently into the clamping structure in a manner such as to minimize bending throughout the entire resonator device. Thereby, bending related loss may be minimized and the Q-factor of the mechanical resonator may be maximized.
G01G 3/16 - Appareils de pesée caractérisés par l'utilisation d'organes déformables par élasticité, p.ex. balances à ressort dans lesquels l'élément de pesée est constitué par un corps solide soumis à une pression ou une traction pendant la pesée utilisant la mesure des variations de la fréquence des oscillations du corps
G01L 1/10 - Mesure des forces ou des contraintes, en général en mesurant les variations de fréquence d'éléments vibrants soumis à une contrainte, p.ex. de cordes tendues
The present invention relates to peptides and peptide analogues with high affinity for the PDZ domains of PICK1. The peptide or peptide analogue interacts with PICK1, blocking the native protein-protein interactions between PICK1 and its natural ligands. The invention furthermore relates to the therapeutic use of these peptides and peptide analogues in prevention and/or treatment of diseases and disorders associated with maladaptive plasticity, drug addiction and neuropathic pain.
Provided herein are glucose-dependent insulinotropic polypeptide (GIP)-derived peptide analogues, for example GIP(3-30), and their use as antagonists of the GIP receptor and for treatment of disorders such as obesity, diabetes mellitus and insulin resistance.
The present disclosure is directed to methods of restoring glial cell K+ uptake in a subject. This method involves selecting a subject having impaired glial cell K+ uptake, and administering, to the selected subject, a RE1-Silencing Transcription factor (REST) inhibitor under conditions effective to restore glial cell K+ uptake. Subjects having impaired glial cell K+ uptake include those at risk of having or having a neuropsychiatric disease or disorder.
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p.ex. benzimidazoles
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention relates to mutant Cpf1 endonucleases having altered activity compared to the wild type Cpf1, and their use to introduce single strand breaks in nucleic acid sequences. Methods for detection and quantification of a nucleic acid sequence are also disclosed. Methods for diagnosis of an infectious disease are also disclosed.
The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
An aqueous gel composition comprising a) water, at least one polysaccharide and at least one high molecular weight polyethylene oxide, wherein the water content is at least 90% by weight of the composition, and b) a local anaesthetic agent or an analgesic agent, for use as a local anaesthetic or analgesic. The aqueous gel shows transparency, lubricity, stringiness, elongation, extensiveness, and cohesiveness while being devoid of taste and smell and non-tacky or non-sticky.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/245 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro du type acide aminobenzoïque, p.ex. procaïne, novocaïne
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p.ex. quinuclidine
A61K 31/445 - Pipéridines non condensées, p.ex. pipérocaïne
Disclosed is a method for controlling a biofilm, for removing a formed biofilm and/or for controlling a growth of microorganisms, preferably bacteria, in an aqueous environment of an industrial manufacturing process including cellulosic fibre material. In the method, a composition including a compound selected from a group consisting of 3-[(4-methylphenyl)sulphonyl]-2-propenenitrile and 4-amino-N-2-thiazolyl-benzenesulphonamide is administered to the aqueous environment of the process.
A subject's level of soluble urokinase type plasminogen activator (suPAR) is checked as part of a risk stratification procedure in a hospital emergency department to help decide whether to admit the subject to the hospital, keep the subject in as a patient, or discharge a patient.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
The present invention relates to a mammalian cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in glycoprotein production where the antibodies with the modifications have an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). The present invention also relates to methods for producing the glycoproteins and compositions comprising the glycoproteins, and their uses.
The present invention relates to a mammalian cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in glycoprotein production where the antibodies with the modifications have an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). The present invention also relates to methods for producing the glycoproteins and compositions comprising the glycoproteins, and their uses.
The present invention relates to a mammalian cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in glycoprotein production where the antibodies with the modifications have an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). The present invention also relates to methods for producing the glycoproteins and compositions comprising the glycoproteins, and their uses.
The present disclosure relates to a method for manufacturing of specially designed substrates for growth of nanostructures and patterned growth on said nanostructures. The present disclosure further relates to nanostructures, in particular hybrid semiconductor nanostructures with patterned growth of superconducting material for use in quantum devices. The presently disclosed method can be utilized for in-situ manufacturing of quantum devices that have not been contaminated by ex-situ processes.
The present disclosure relates to compositions comprising insulin and to be administered rectally for treatment of inflammatory bowel diseases and inflammation-induced colorectal tumour and/or cancer.
Mirtazapine is useful for the treatment and/or prophylaxis of medication overuse headache based on tension-type headache. Moreover, a pharmaceutical composition and/or the use of mirtazapine for the manufacture of a medicament, are useful against medication overuse headache based on tension-type headache, and the treatment of medication overuse headache based on tension-type headache.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.
A method for obtaining a betalain pigment composition from red beet plants comprising pre-harvest foliar spraying of an ethylene-generating compound and the use of the obtained betalain pigment composition for coloring of an edible product.
A23L 5/43 - Adjonction de colorants ou de pigments, p.ex. en combinaison avec des azurants optiques en utilisant des colorants ou des pigments organiques d'origine naturelle, leurs doublons artificiels ou leurs dérivés
A23K 20/179 - Agents colorants, p.ex. agents de pigmentation ou de teinture
A01G 22/25 - Légumes-racines, p.ex. pommes de terre, ignames, betterave ou wasabi
The present disclosure relates to a system for generating a predefined electrical signal in an MR scanner for use in electrical stimulation of a subject during MRI or functional MRI of said subject, wherein said MR scanner is located inside a shielded MRI room. The system comprises a control unit to be located outside the MRI room for generating an electrical signal and an electrical to optical converter to be located outside the MRI room for converting said electrical signal to a corresponding optical signal. An optical transmitting element, such as an optical fiber, is used for transmitting the optical signal into the MRI room, and an optical to electrical converter is used for converting the optical signal to said predefined electrical signal for electrical stimulation of the subject during magnetic resonance imaging. The optical to electrical converter is configured for being located inside the MRI room and for operation during magnetic resonance imaging.
A61N 1/08 - Aménagements ou circuits de surveillance, de protection, de commande ou d'indication
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
H04B 1/58 - Dispositions hybrides, c. à d. dispositions pour la transition d’une transmission bilatérale sur une voie à une transmission unidirectionnelle sur chacune des deux voies ou vice versa
57.
Method for growing somatic embryos of conifers into trees
Abies and to the use of plants thus obtained. The invention concerns a method for treating and growing somatic embryos under conditions that induce and stimulate root growth, that induce and stimulate shoot formation and increases the survival rate of the embryos, plantlets and emblings. The emblings can subsequently be grown into trees. Trees derived from somatic embryogenesis and grown according to the method of the invention are of a very homogeneous appearance and quality, which is preferred in the production of trees such as Christmas trees thereby reducing the wastage rate.
The invention relates to a virus like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, asthma, and/or allergy diseases/disorders.
The present invention relates to small molecules interfering with the conformational space of the TONSL ARD occupied by the histone H4 tail. These small molecules targets the binding pocket of TONSL encompassing the H4 residues K12-R23 and act by preventing or disrupting the binding of the H4 tail K12-R23 with the TONSL ARD via direct competition or via allosteric disruption of the binding pocket.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/00 - Préparations médicinales contenant des peptides
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
G16B 15/30 - Ciblage de médicament à l’aide de données structurelles; Prévision d’amarrage ou de liaison moléculaire
G16C 20/50 - Conception moléculaire, p.ex. de médicaments
60.
Virus-like particle with efficient epitope display
The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.
Disclosed are glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues GIPS-30 and GIP3-30 which are antagonists of the GIP receptor and comprises at least one fatty acid molecule to increase half-life while maintaining antagonistic properties.
The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
A61P 3/08 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/566 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
63.
Optically detectable marker including luminescent dopants and system and method for reading such markers
An optically detectable marker having a matrix material, which is doped with individual luminescent dopants, including a first luminescent dopant and a second luminescent dopant. The first luminescent dopant includes a first unique absorption band such that the first dopant may be excited by illumination of a first wavelength. The first dopant is distributed in the matrix material so as to form a first spatial pattern in the matrix material, which pattern may be optically detected by illuminating the marker by a light source illuminating light of the first wavelength. The second luminescent dopant includes a second unique absorption band such that the second dopant may be excited by illumination of a second wavelength, different from the first. The second dopant is distributed in the matrix material so as to form a second spatial pattern in the matrix material, which pattern may be optically detected by illuminating the marker by a light source illuminating light of the second wavelength.
Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.
The present invention relates to a vaccine comprising a nucleic acid construct such as a DNA construct especially a nucleic acid construct comprising sequences encoding invariant chain operatively linked to antigenic protein or peptide encoding sequences. The present vaccine stimulates an enhanced immune response.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
The present disclosure relates to nanoscale device comprising an elongated crystalline nanostructure, such as a nanowire crystal, a nanowhisker crystal or a nanorod crystal, and a method for producing thereof. One embodiment relates to a nanoscale device comprising an elongated crystalline semiconductor nanostructure, such as a nanowire (crystal) or nanowhisker (crystal) or nanorod (crystal), having a plurality of substantially plane side facets, a crystalline structured first facet layer of a superconductor material covering at least a part of one or more of said side facets, and a second facet layer of a superconductor material covering at least a part of the first facet layer, the superconductor material of the second facet layer being different from the superconductor material of the first facet layer, wherein the crystalline structure of the semiconductor nanostructure is epitaxially matched with the crystalline structure of the first facet layer on the interface between the two crystalline structures.
H01L 39/02 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
B82Y 40/00 - Fabrication ou traitement des nanostructures
H01L 29/43 - Electrodes caractérisées par les matériaux dont elles sont constituées
H01L 29/66 - Types de dispositifs semi-conducteurs
H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
H01L 29/41 - Electrodes caractérisées par leur forme, leurs dimensions relatives ou leur disposition relative
H01L 39/24 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement des dispositifs couverts par ou de leurs parties constitutives
H01L 39/22 - Dispositifs comportant une jonction de matériaux différents, p.ex. dispositifs à effet Josephson
H01L 39/12 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails caractérisés par le matériau
C23C 14/28 - Evaporation sous vide par énergie éléctromagnétique ou par rayonnement corpusculaire
The present application provides inter alia a fusion protein comprising a polypeptide wherein the polypeptide consists of a fragment of invariant chain which is operably linked to an antigenic sequence and wherein the fragment of invariant chain consists of a portion of residues 17-97 of SEQ ID NO: 1, wherein the portion comprises at least 5 contiguous residues from residues 77-92 of SEQ ID NO: 1.
The present invention relates to a method for display of a plurality of mammalian glycans on cells or proteins for probing biological interactions and identifying glycan structures involved. A plurality of mammalian cells is genetically engineered in a combinatorial approach to differentially express the human glycome. Genetic engineering of the cell produces a plurality isogenic cells with different repertoires of glycosyltransferases and display of glycans that is used to interpret biological interactions. The plurality of engineered cells display glycans with and without the context of specific proteins exogeneously expressed, and is useful for detection and optimization of biological interactions for example binding of lectins, antibodies, viruses and bacteria and glycoproteins.
C12P 21/00 - Préparation de peptides ou de protéines
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
69.
Semiconductor Josephson junction and a transmon qubit related thereto
The present disclosure relates to semiconductor based Josephson junctions and their applications within the field of quantum computing, in particular a tuneable Josephson junction device has been used to construct a gateable transmon qubit. One embodiment relates to a Josephson junction comprising an elongated hybrid nanostructure comprising superconductor and semiconductor materials and a weak link, wherein the weak link is formed by a semiconductor segment of the elongated hybrid nanostructure wherein the superconductor material has been removed to provide a semiconductor weak link.
H01L 39/02 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
B82Y 40/00 - Fabrication ou traitement des nanostructures
H01L 29/43 - Electrodes caractérisées par les matériaux dont elles sont constituées
H01L 29/66 - Types de dispositifs semi-conducteurs
H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
H01L 29/41 - Electrodes caractérisées par leur forme, leurs dimensions relatives ou leur disposition relative
H01L 39/24 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement des dispositifs couverts par ou de leurs parties constitutives
H01L 39/22 - Dispositifs comportant une jonction de matériaux différents, p.ex. dispositifs à effet Josephson
H01L 39/12 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails caractérisés par le matériau
C23C 14/28 - Evaporation sous vide par énergie éléctromagnétique ou par rayonnement corpusculaire
The present disclosure relates to a method of inducing weight loss and/or preventing weight gain in a subject affected by administering certain diets selected based on the fasting blood glucose and/or the fasting insulin of the subject. The present disclosure further provides personalized dietary instruction, based on the fasting blood glucose and/or the fasting insulin of a subject, with the potential to improve the weight loss and prevent weight regain. The present disclosure further relates to methods for predicting weight loss success and classifying responsiveness of a subject to a certain diet as well as methods for selecting a weight loss or a weight gain diet for a subject based on the fasting blood glucose and/or the fasting insulin of the subject.
The present invention relates to a cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in improvement of pharmacokinetic properties, i.e. by attaching PEG chains to proteins. The present invention also relates to methods for producing the antibodies and compositions comprising the antibodies, and their uses.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12P 21/00 - Préparation de peptides ou de protéines
C07K 14/61 - Hormone de croissance (GH) (Somatotropine)
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
C12N 9/64 - Protéinases provenant de tissu animal, p.ex. rennine
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
The invention relates to methods for preparing a beverage comprising at least 2 g/L β-glucan, wherein said β-glucans have an average molecular weight in the range of 80 to 200 kDa. The methods involve mashing barley kernels comprising at least 10% β-glucans and having a ratio of DP3/DP4 in said β-glucan of at least 3 in the presence of α-amylase and endo-1,3(4)-β-glucanase activity. The beverages have a viscosity providing a good mouth-feel, and at the same time they comprise β-glucans, which are able to aid in lowering LDL cholesterol levels. The beverages are generally stable and can be stored for months at room temperature without a significant decrease in β-glucan content.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
The present disclosure relates to a device and method for forming efficient quantum devices, in particular quantum devices that have not been contaminated in ex-situ processes. In particular the presently disclosed method can be applied for manufacturing of a Josephson junction which is an element in a tunable superconducting qubit. One embodiment relates to a method for in-situ production of a barrier/gap in the surface layer(s) of an elongated nanostructure, the method comprising the steps of providing at least one elongated device nanostructure on a substrate in a vacuum chamber having at least one deposition source, providing at least one elongated shadow nanostructure in said vacuum chamber, and depositing at least a first facet layer on at least a part of the device nanostructure(s) and the shadow nanostructure(s) by means of said deposition source, wherein the deposition source, the device nanostructure and the shadow nanostructure during deposition are arranged such that the shadow nanostructure covers and forms a shadow mask on at least a part of the device nanostructure thereby forming a gap in the first facet layer deposited on the device nanostructure.
H01L 21/00 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de dispositifs à semi-conducteurs ou de dispositifs à l'état solide, ou bien de leurs parties constitutives
H01L 39/24 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement des dispositifs couverts par ou de leurs parties constitutives
C23C 14/04 - Revêtement de parties déterminées de la surface, p.ex. au moyen de masques
C30B 29/60 - Monocristaux ou matériaux polycristallins homogènes de structure déterminée caractérisés par leurs matériaux ou par leur forme caractérisés par la forme
H01L 39/22 - Dispositifs comportant une jonction de matériaux différents, p.ex. dispositifs à effet Josephson
G06N 10/00 - Informatique quantique, c. à d. traitement de l’information fondé sur des phénomènes de mécanique quantique
C23C 14/28 - Evaporation sous vide par énergie éléctromagnétique ou par rayonnement corpusculaire
C30B 23/04 - Dépôt suivant une configuration déterminée, p.ex. en utilisant des masques
The invention provides methods for identifying biomarkers in a patient's microbiota to predict a patient's response to a predetermined diet to promote weight loss and methods of promoting weight loss in the patient by optimizing the patient's diet in accordance with the biomarkers identified in the patient's gut microbiota. The methods of the invention can also be used to manage or maintain weight, i.e., prevent or inhibit weight gain, in a patient who is of normal weight or is overweight or obese.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
The invention described materials and methods for producing oxidized 13R-MO, such as forskolin. In particular, the invention describes P450s involved in oxidation of 13R-MO including CYP76AH8, CYP76AH11, CYP76AH15, CYP76AH17, CYP71D381 and CYP76AH9. Host organisms expressing one or more of these P450s are useful in the production of oxidized 13R-MO.
C12P 17/06 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'oxygène comme unique hétéro-atome du cycle contenant un hétérocycle à six chaînons, p.ex. fluorescéine
The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.
Provided herein are glucose-dependent insulinotropic polypeptide (GIP)-derived peptide analogues, for example GIP(3-30), and their use as antagonists of the GIP receptor and for treatment of disorders such as obesity, diabetes mellitus and insulin resistance.
Herein provided are peptide inhibitors and methods for treating polyglutamine (polyQ) diseases. Also disclosed are related compositions and kits for therapeutic use in the treatment of polyQ diseases.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
81.
Light-driven system and methods for chemical modification of an organic substrate
The present disclosure relates to a light-driven system which is able to chemically modify an organic substrate with high efficiency and in a cost-effective manner. Also provided are methods for chemically modifying an organic substrate using the present systems and methods for manufacturing such systems.
An optical device comprising a planar waveguide and a quantum emitter is presented. The planar waveguide comprises a longitudinal extending guiding region with a first side and a second side. A first nanostructure is arranged on the first side of the guiding region, and a second nanostructure is arranged on the second side of the guiding region. The planar waveguide includes a first longitudinal region where the first nanostructure and the second nanostructure are arranged substantially glide-plane symmetric about the guiding region of the planar waveguide, and the quantum emitter is coupled to the first longitudinal region of the planar waveguide.
G02B 6/122 - Elements optiques de base, p.ex. voies de guidage de la lumière
B82Y 20/00 - Nano-optique, p.ex. optique quantique ou cristaux photoniques
G02B 1/00 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES Éléments optiques caractérisés par la substance dont ils sont faits; Revêtements optiques pour éléments optiques
G02B 6/12 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES - Détails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p.ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré
The present disclosure relates to a method for producing a network of interconnected nanostructures comprising the steps of: providing a substantially plane substrate; growing a plurality of elongated nanostructures from the substrate; kinking the growth direction of at least a part of the nanostructures such that at least part of the kinked nanostructures are growing in a network plane parallel to the substrate, and creating one or more network(s) of interconnected kinked nanostructures in the network plane, wherein a dielectric support layer is provided below the network plane to support said network(s) of interconnected nanostructures.
C30B 29/60 - Monocristaux ou matériaux polycristallins homogènes de structure déterminée caractérisés par leurs matériaux ou par leur forme caractérisés par la forme
C30B 29/66 - Cristaux de forme géométrique complexe, p.ex. tubes, cylindres
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
84.
Isolation of bona fide pancreatic progenitor cells
The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
A61P 3/08 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/566 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
85.
Virus-like particle with efficient epitope display
The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.
Solvent consumption in supercritical ethanol, propanol or butanol treatment of either refined pre-extracted lignin or comparatively impure lignin-rich solid residual from hydrothermally pretreated lignocellulosic biomass can be minimized by conducting the reaction at very high loading of lignin to solvent. Comparatively impure, crude lignin-rich solid residual can be directly converted by supercritical alcohol treatment to significantly diesel-soluble lignin oil without requirement for pre-extraction or pre-solubilization of lignin or for added reaction promoters such as catalysts, hydrogen donor co-solvents, acids, based or H2 gas. O:C ratio of product oil can readily be obtained using crude lignin residual in such a process at levels 0.20 or lower.
C10G 1/04 - Production de mélanges liquides d'hydrocarbures à partir de schiste bitumineux, de sable pétrolifère ou de matières carbonées solides non fusibles ou similaires, p.ex. bois, charbon par extraction
C10L 1/02 - Combustibles carbonés liquides à base essentielle de composants formés uniquement de carbone, d'hydrogène et d'oxygène
C10L 1/08 - Combustibles carbonés liquides à base essentielle de mélanges d'hydrocarbures pour allumage par compression
C10G 3/00 - Production de mélanges liquides d'hydrocarbures à partir de matières organiques contenant de l'oxygène, p.ex. huiles, acides gras
C10L 1/18 - Composés organiques contenant de l'oxygène
C10L 5/44 - Combustibles solides à base essentielle de matières d'origine non minérale de matières végétales
C10L 9/08 - Traitement des combustibles solides en vue d'améliorer leur combustion par traitement thermique, p.ex. calcination
The present invention relates to a mammalian cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in glycoprotein production where the antibodies with the modifications have an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). The present invention also relates to methods for producing the glycoproteins and compositions comprising the glycoproteins, and their uses.
Processes for producing cellulose microfibrils from herbaceous plant material using enzyme compositions, the cellulose microfibrils obtained from the processes and their uses, and compositions comprising the cellulose microfibrils are described.
An optical device comprising a single-photon device, which is coupled to a planar waveguide is described. The planar waveguide comprises a nanostructured section, which includes a longitudinal extending guiding region with a first side and a second side, a first nanostructure arranged on the first side of the guiding region, and a second nanostructure arranged on the second side of the guiding region. The nanostructured section comprises a slow-mode section, in which the single-photon device is positioned or embedded, and in which the first nanostructure and second nanostructure suppress spontaneous emission into other modes. The planar waveguide further comprises a fiber coupler for coupling light out of the planar waveguide and into an optical fiber, the fiber coupler preferably being adapted to match a field profile of an optical fiber.
G02B 6/12 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES - Détails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p.ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré
G02B 6/122 - Elements optiques de base, p.ex. voies de guidage de la lumière
C09K 11/74 - Substances luminescentes, p.ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant de l'arsenic, de l'antimoine ou du bismuth
G02B 6/30 - Moyens de couplage optique pour usage entre fibre et dispositif à couche mince
G02B 6/124 - Lentilles géodésiques ou réseaux intégrés
G02B 6/10 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES - Détails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p.ex. des moyens de couplage du type guide d'ondes optiques
G02F 1/035 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des céramiques ou des cristaux électro-optiques, p.ex. produisant un effet Pockels ou un effet Kerr dans une structure de guide d'ondes optique
B82Y 20/00 - Nano-optique, p.ex. optique quantique ou cristaux photoniques
90.
Nanoscale device comprising an elongated crystalline nanostructure
The present disclosure relates to nanoscale device comprising an elongated crystalline nanostructure, such as a nanowire crystal, a nanowhisker crystal or a nanorod crystal, and a method for producing thereof. One embodiment relates to a nanoscale device comprising an elongated crystalline semiconductor nanostructure, such as a nanowire (crystal) or nanowhisker (crystal) or nanorod (crystal), having a plurality of substantially plane side facets, a crystalline structured first facet layer of a superconductor material covering at least a part of one or more of said side facets, and a second facet layer of a superconductor material covering at least a part of the first facet layer, the superconductor material of the second facet layer being different from the superconductor material of the first facet layer, wherein the crystalline structure of the semiconductor nanostructure is epitaxially matched with the crystalline structure of the first facet layer on the interface between the two crystalline structures.
H01L 39/24 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement des dispositifs couverts par ou de leurs parties constitutives
H01L 39/02 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
B82Y 40/00 - Fabrication ou traitement des nanostructures
H01L 29/43 - Electrodes caractérisées par les matériaux dont elles sont constituées
H01L 29/66 - Types de dispositifs semi-conducteurs
H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
H01L 29/41 - Electrodes caractérisées par leur forme, leurs dimensions relatives ou leur disposition relative
H01L 39/22 - Dispositifs comportant une jonction de matériaux différents, p.ex. dispositifs à effet Josephson
H01L 39/12 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails caractérisés par le matériau
C23C 14/28 - Evaporation sous vide par énergie éléctromagnétique ou par rayonnement corpusculaire
The present disclosure relates to semiconductor based Josephson junctions and their applications within the field of quantum computing, in particular a tuneable Josephson junction device has been used to construct a gateable transmon qubit. One embodiment relates to a Josephson junction comprising an elongated hybrid nanostructure comprising superconductor and semiconductor materials and a weak link, wherein the weak link is formed by a semiconductor segment of the elongated hybrid nanostructure wherein the superconductor material has been removed to provide a semiconductor weak link.
H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
H01L 39/02 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
B82Y 40/00 - Fabrication ou traitement des nanostructures
H01L 29/43 - Electrodes caractérisées par les matériaux dont elles sont constituées
H01L 29/66 - Types de dispositifs semi-conducteurs
H01L 39/24 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement des dispositifs couverts par ou de leurs parties constitutives
H01L 29/41 - Electrodes caractérisées par leur forme, leurs dimensions relatives ou leur disposition relative
H01L 39/22 - Dispositifs comportant une jonction de matériaux différents, p.ex. dispositifs à effet Josephson
H01L 39/12 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails caractérisés par le matériau
C23C 14/28 - Evaporation sous vide par énergie éléctromagnétique ou par rayonnement corpusculaire
The invention described materials and methods for producing oxidized 13R-MO, such as forskolin. In particular, the invention describes P450s involved in oxidation of 13R-MO including CYP76AH8, CYP76AH11, CYP76AH15, CYP76AH17, CYP71D381 and CYP76AH9. Host organisms expressing one or more of these P450s are useful in the production of oxidized 13R-MO.
C12N 9/04 - Oxydoréductases (1.), p.ex. luciférase agissant sur des groupes CHOH comme donneurs, p.ex. oxydase de glucose, déshydrogénase lactique (1.1)
C12P 17/06 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'oxygène comme unique hétéro-atome du cycle contenant un hétérocycle à six chaînons, p.ex. fluorescéine
The present invention relates to methods for preparing patchoulol, β-santalene, and sclareol in transgenic moss cells that include heterologous nucleic acid molecules encoding a polypeptide or synthase capable of using FPP or GGPP as a substrate. Methods for producing the transgenic moss cell, as well as the transgenic moss cell itself are also disclosed.
C12P 7/02 - Préparation de composés organiques contenant de l'oxygène contenant un groupe hydroxyle
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
C12P 15/00 - Préparation de composés contenant au moins trois carbocycles condensés
The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analog comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analog thereof, and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analog thereof, wherein an amino-terminal residue of the peptide is N-alkylated. Alternatively the compound of the invention comprises a first peptide or peptide analog linked to a second peptide or peptide analog by a linker, where the first and second peptide or peptide analog each comprise at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analog thereof, and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analog thereof.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
C07K 5/113 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes carboxyle que de groupes amino, ou leurs dérivés, p.ex. Asp, Glu, Asn
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
95.
Agrobacterium rhizogenes transformation and expression of rol genes in kalanchoe
The present invention relates to methods for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing non-fat energy uptake in the gastrointestinal tract of a mammal in order to prevent a positive non-fat energy balance, weight gain, overweight and obesity, and to induce a negative non-fat energy balance and weight loss in subjects who wish to reduce their body weight. In particular, feed, food and/or beverages and dietary supplements of the present invention comprises mucilage such as flax seed mucilage and/or one or more active compounds of mucilage useful for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing the digestibility of non-fat energy in the gastrointestinal tract of a mammal.
A23L 1/29 - Modification de la qualité nutritive des aliments; Produits diététiques ( A23L 1/09 a priorité;substituts diététiques du sel A23L 1/22)
A61K 33/06 - Aluminium, calcium ou magnésium; Leurs composés
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à quatre chaînons, p.ex. taxol
A61K 31/536 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes carbocycliques
A61K 36/55 - Linaceae (famille du lin), p.ex. Linum
A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine fongique, p.ex. de champignons
A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A23L 33/22 - Parties fibreuses broyées de plantes, p.ex. bagasse ou pulpe
The invention relates to methods for producing vanillin and related compounds. The methods involve use of a vanillin synthase capable of catalyzing side chain cleavage of ferulic acid to form vanillin. The invention also relates to host organisms expressing such vanillin synthases useful in the methods.
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
A23L 27/24 - ALIMENTS, PRODUITS ALIMENTAIRES OU BOISSONS NON ALCOOLISÉES NON COUVERTS PAR LES SOUS-CLASSES OU ; LEUR PRÉPARATION OU TRAITEMENT, p.ex. CUISSON, MODIFICATION DES QUALITÉS NUTRITIVES, TRAITEMENT PHYSIQUE ; CONSERVATION DES ALIMENTS OU PRODUITS ALIMENTAIRES EN GÉNÉRAL Édulcorants artificiels; Sels de table; Substituts diététiques du sel; Leur préparation ou leur traitement Épices, agents aromatiques ou condiments synthétiques préparés par fermentation
C12N 9/04 - Oxydoréductases (1.), p.ex. luciférase agissant sur des groupes CHOH comme donneurs, p.ex. oxydase de glucose, déshydrogénase lactique (1.1)
C12P 7/22 - Préparation de composés organiques contenant de l'oxygène contenant un groupe hydroxyle aromatiques
C12P 19/46 - Préparation d'O-glucosides, p.ex. glucosides avec un atome d'oxygène du radical saccharide lié à un radical cyclohexyle, p.ex. kasugamycine
This invention relates to methods for the detection of a bovine that is affected by or carrier of brachyspina. It is based on the identification of a 3.3 Kb deletion in the bovine FANCI gene that is shown to cause the brachyspina syndrome. The present invention provides methods and uses for determining whether a bovine is affected by or carrier of brachyspina by analyzing its genomic DNA or its RNA. The methods can be used to perform marker assisted selection or genomic selection for increased fertility in said bovine.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
99.
High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
The invention provides novel potent inhibitors of the ternary protein complex of nNOS, PSD-95, and the NMDA receptor and pharmaceutical compositions comprising the inhibitors for prophylaxis and/or treatment of excitotoxic-related disease and chronic pain conditions in a subject. The inhibitors are dimeric PSD-95 inhibitors comprising a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, wherein the first and the second peptide or peptide analogue comprise at least four amide-bonded residues having a sequence YTXV (SEQ ID NO: 5) or YSXV (SEQ ID NO: 6), wherein a. Y is selected from among E, Q, and A, or an analogue thereof, and b. X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, and wherein a Cell Penetrating Peptide (CPP) is linked to the linker or to an amino acid side chain of the first and second peptide or peptide analogue. The linker can be a PEG or NPEG linker.
brevets
